Accelerated and intensified manufacturing of an adenovirus‐vectored vaccine to enable rapid outbreak response

Abstract

AbstractThe Coalition for Epidemic Preparedness Innovations' “100‐day moonshot” aspires to launch a new vaccine within 100 days of pathogen identification, followed by large‐scale vaccine availability within the “second hundred days.” Here, we describe work to optimize adenoviral vector manufacturing for rapid response, by minimizing time to clinical trial and first large‐scale supply, and maximizing output from the available manufacturing footprint. We describe a rapid virus seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a perfusion‐based upstream production process, designed to maximize output while retaining simplicity and suitability for existing manufacturing facilities. This improves upstream volumetric productivity of ChAdOx1 nCoV‐19 by approximately fourfold and remains compatible with the existing downstream process, yielding drug substance sufficient for 10,000 doses from each liter of bioreactor capacity. This accelerated manufacturing process, along with other advantages such as thermal stability, supports the ongoing value of adenovirus‐vectored vaccines as a rapidly adaptable and deployable platform for emergency response.